Cancer Genetics, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 5.751 million compared to USD 7.305 million a year ago. Operating loss was USD 8.183 million compared to USD 5.703 million a year ago. Net loss was USD 8.001 million compared to USD 6.708 million a year ago. Basic loss per share was USD 3.16 compared to USD 3.48 a year ago. Basic loss per share from continuing operations was USD 3.18 compared to USD 3.57 a year ago.